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Microglia prevent beta-amyloid plaque
formation in the early stage of an
Alzheimer’s disease mouse model with
suppression of glymphatic clearance
Weixi Feng1,2, Yanli Zhang1,2, Ze Wang1,2, Hanrong Xu1,2, Ting Wu3, Charles Marshall4, Junying Gao1,2* and
Ming Xiao1,2*
Abstract
Background: Soluble beta-amyloid (Aβ) can be cleared from the brain through various mechanisms including
enzymatic degradation, glial cell phagocytosis, transport across the blood-brain barrier, and glymphatic clearance.
However, the relative contribution of each clearance system and their compensatory effects in delaying the
pathological process of Alzheimer’s disease (AD) are currently unknown.
Methods: Fluorescent trace, immunofluorescence, and Western blot analyses were performed to compare
glymphatic clearance ability and Aβ accumulation among 3-month-old APP695/PS1-dE9 transgenic (APP/PS1) mice,
wild-type mice, aquaporin 4 knock out (AQP4−/−) mice, and AQP4−/−/APP/PS1 mice. The consequence of selectively
eliminating microglial cells, or downregulating apolipoprotein E (apoE) expression, on Aβ burden, was also
investigated in the frontal cortex of AQP4−/−/APP/PS1 mice and APP/PS1 mice.
Results: AQP4 deletion in APP/PS1 mice significantly exaggerated glymphatic clearance dysfunction, and
intraneuronal accumulation of Aβ and apoE, although it did not lead to Aβ plaque deposition. Notably, microglia,
but not astrocytes, increased activation and phagocytosis of Aβ in the cerebral cortex of AQP4−/−/APP/PS1 mice,
compared with APP/PS1 mice. Selectively eliminating microglia in the frontal cortex via local injection of clodronate
liposomes resulted in deposition of Aβ plaques in AQP4−/−/APP/PS1 mice, but not APP/PS1 mice. Moreover,
knockdown of apoE reduced intraneuronal Aβ levels in both APP/PS1 mice and AQP4−/−/APP/PS1 mice, indicating
an inhibitory effect of apoE on Aβ clearance.
Conclusion: The above results suggest that the glymphatic system mediated Aβ and apoE clearance and microglia
mediated Aβ degradation synergistically prevent Aβ plague formation in the early stages of the AD mouse model.
Protecting one or both of them might be beneficial to delaying the onset of AD.
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Background
Alzheimer’s disease (AD) is one of the most common
neurodegenerative diseases and is partially attributed to
abnormal aggregation of oligomerized beta-amyloid
(Aβ). Excessive accumulation of toxic forms of Aβ is
mainly due to an imbalance between its production and
clearance [1, 2]. Failure of Aβ clearance plays a crucial
role in the etiology of AD, especially sporadic AD [3–5].
Therefore, exploring mechanisms and corresponding
strategies of Aβ clearance will be a help in the preven-
tion and treatment of AD.
A variety of clearance mechanisms, such as glial
phagocytes, enzymatic degradation, and transport across
the brain barriers, participate in the clearance of soluble
brain Aβ peptides [6–8]. Recently, the glymphatic sys-
tem, also known as the paravascular pathway, is impli-
cated in clearance of a major portion of extracellular Aβ
from the brain [9–11]. This route for Aβ clearance is
mainly dependent on the bulk flow of interstitial fluid
(ISF), mediated by astroglial aquaporin 4 (AQP4) [12–
15]. AQP4, a water channel localized to perivascular end
feet of astrocytes and ependymal cells, is responsible for
rapid transport of water into and out of the brain paren-
chyma [16].
The glymphatic clearance malfunction is related to
mislocalization of AQP4 due to reactive astroglosis in
various mouse models, including brain aging [11], AD
[17] and mild traumatic brain injury [18]. We have re-
ported that knockout of the Aqp4 gene (AQP4−/−) ag-
gravates brain Aβ accumulation and cognitive deficits of
12-month-old APP/PS1 mice [19]. AQP4-dependent
glymphatic clearance potentially serves as a therapeutic
target for abnormal aggregation of macromolecule-
related neurodegenerative disorders including AD.
However, the consequences of glymphatic dysfunc-
tions in the onset of AD and interactive roles of the
abovementioned Aβ clearance systems in delaying or
retarding AD progress are yet to be elucidated. In the
present study, we compared glymphatic clearance ability
among 3-month-old AQP4−/−/APP/PS1 mice, APP/PS1
mice, AQP4−/− mice, and wild-type (WT) mice. We also
investigated the consequence of selectively eliminating
microglial cells or downregulating apolipoprotein E
(apoE) expression on Aβ burden in the frontal cortex of
AQP4−/−/APP/PS1 mice and APP/PS1 mice.
Methods
Animals
APP695/PS1-dE9 transgenic (APP/PS1) mice with a
C57BL/6J background were obtained from Jackson
Laboratories. These mice were bred with AQP4−/− mice
on a CD1 genetic background that were previously
established in our laboratory [20]. F1 offspring were ge-
notyped for APP and PS1 and for Aqp4 [19]. Female and
male AQP4+/−/APP/PS1 mice were then mated to gener-
ate F2 offspring. AQP4+/−/APP/PS1 mice and AQP4+/−
mice were genotyped from these F2 littermates and
interbred at 3 months of age to generate AQP4+/+ (WT)
mice, APP/PS1 mice, AQP4−/− mice and AQP4−/−/APP/
PS1 mice. These mice were maintained until they
reached 2 or 3 months of age for experiments. Animal
experiments were performed in accordance with the rec-
ommendations in the Guide for the Care and Use of La-
boratory Animals of Nanjing Medical University. All of
the animals were handled according to approved by the
Institutional Animal Care and Use Committee (NMU).
Tracer injection
Anesthetized mice were fixed to a stereotaxic frame. For
intracisternal tracer injection [13], the membrane of the
cisterna magna was exposed and carefully pierced by a
pulled glass capillary with a 10-μm tip diameter attached
to a syringe. Then, 5 μl of 0.5% Texas Red-dextran (TR-
d3, 3 kD, ThermoFisher, #D3328) dissolved in artificial
cerebrospinal fluid (CSF) was injected, at a rate of 1 μl/
min by a micropump (TJ-2A/L07-2A, Suzhou Wen Hao
Chip Technology Co. Ltd., Jiangsu, China). For intras-
triatal injection [13], the skin was opened and the skull
was exposed. A burr hole was made with a hand-held
drill on the coordinates: + 0.5 mm anterior/posterior, +
2.0 mm medial/lateral, and + 3.25 mm dorsal/ventral
from bregma. The pulled glass capillary was implanted
into the brain parenchyma. A 1 μl volume of 0.5% TR-d3
was then perfused, at a rate of 0.1 μl/min via the micro-
pump. The micropipette remained in place for 5 min,
then withdrew very slowly to avoid any possible back-
flow. Thirty minutes after intracisternal, or 1 h after
intrastriatal injection, and with a second supplementary
anesthesia, mice were transcardially perfused with fixa-
tive containing 4% paraformaldehyde (PFA) in 0.1M
phosphate buffer. The brains and deep cervical lymph
nodes (dcLNs) were removed and post-fixed for 24 h.
Cerebral injection of clodronate liposomes or adeno-
associated virus (AAV) encoding apoE siRNAs
Clodronate liposomes (Liposoma, Amsterdam, The
Netherlands; #P22JO419) were injected into the frontal
cortex to deplete local microglia, as previously reported
[21]. Three-month-old APP/PS1 mice and AQP4−/−/
APP/PS1 mice were intracerebrally administrated 1.5 μl
clodronate liposomes, or PBS liposomes, for 5 min (co-
ordinates relative to Bregma: + 1.34 mm anterior/poster-
ior, ± 1.00 mm medial/lateral, and + 1.00 mm dorsal/
ventral). The microsyringe was withdrawn 2min after
injection. In order to downregulate expression of apoE
in the frontal cortex, a single dose (1010 viral particles in
1.5 μl) of AAV encoding siRNAs targeting for apoE was
administrated into the frontal cortex of 2-month-old
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APP/PS1 mice or AQP4−/−/APP/PS1 mice with the same
stereotaxic parameters mentioned above. A subgroup of
APP/PS1 mice and AQP4−/−/APP/PS1 mice received in-
tracerebral injection of AAV encoding a non-sense se-
quence was used as controls. Mice were sacrificed for
the Aβ-related pathological analyses, 5 days after clodro-
nate liposome injection or 1 month after AVV injection,
respectively.
Section and tissue preparation
Following anesthesia, mice were transcardially perfused
with 0.9% saline, followed by 4% paraformaldehyde
(PFA) by perfusion pump (Cole-parmer, USA). Brain tis-
sues and dcLNs were then post-fixed in 4% PFA over-
night and dehydrated in 20% sucrose solution dissolved
in 0.01M PBS for 3 days. Sections were cut at 30 μm on
a cryostat (Leica, Wetzlar, Germany) and mounted onto
gelatin-coated slides. For CSF tracer experiments, PFA
post-fixed forebrain tissues were coronally sliced on a
vibratome (Leica) at 100 μm and mounted onto gelatin-
coated slides in sequence. For biochemical analyses,
anesthetized mice were euthanized by decapitation. The
cerebral cortex was promptly dissected. Tissues were
flash frozen in liquid nitrogen and stored at − 80 °C
awaiting analysis.
Immunofluorescence
Brain slices were blocked for 1 h at room temperature
with 5% BSA, incubated with primary antibodies includ-
ing rabbit anti-NeuN (1:500; Abcam, #ab177487), mouse
anti-glial fibrillary acidic protein (GFAP) (1:800; Milli-
pore, #AB3594), rabbit anti-GFAP (1:400; Abcam,
#ab7260), rabbit anti-ionized calcium-binding adaptor
molecule 1 (Iba1) (1:1000; Wako, #019-19741), rat anti-
CD68 (1:100; bio-rad, #MCA1957), goat anti-lysosome-
associated membrane glycoprotein 1 (Lamp1) (1:200,
R&D systems, #AF4320), mouse anti-glutamine synthe-
tase (GS) (1:100, BD, #610517), rabbit anti-Aβ1–40 (1:
250; CST, #12990), mouse anti-total Aβ (Aβ1–16) (1:
1000; Covance, # 803001), rabbit anti-AQP4 (1:400;
Millipore, #AB3594), rabbit anti-apoE (1:200; Abcam,
#ab20874), or mouse anti-apoE (1:200; Abcam, #ab1906)
overnight at 4 °C. After extensive rinsing, sections were
incubated for 2 h at room temperature with AF488-
conjugated donkey anti-mouse IgG (1:1000, Thermo-
Fisher, #A21202), AF488-conjugated donkey anti-rabbit
IgG (1:1000, ThermoFisher, #A21206), AF555-
conjugated donkey anti-rabbit IgG (1:1000, Thermo-
Fisher, #A31572), AF555-conjugated donkey anti-mouse
IgG (1:1000, ThermoFisher, #A31570), AF647-
conjugated donkey anti-mouse IgG (1:1000, Thermo-
Fisher, #A31571), or AF488-conjugated donkey anti-goat
IgG (1:1000, ThermoFisher, #A11055). The sections
were washed for 3 × 5min in PBS containing 1.5 μM 4′,
6-diamidino-2-phenylindole (DAPI, Invitrogen,
#D21490), then cover slipped with buffered PBS/
glycerol.
Western blot
Cerebral cortex extracts were loaded onto 10–16% Tris/
tricine SDS gels and transferred to nitrocellulose mem-
branes before overnight incubation with one of the fol-
lowing primary antibodies: mouse anti-β-site amyloid
precursor protein-cleaving enzyme 1 (BACE1) (1:1000;
Millipore, #MAB5308), anti-PS1 (1:1000; Sigma-Aldrich,
#PRS4203), anti-neprilysin (NEP) (1:1000; Millipore,
#AB4348), anti-insulin-degrading enzyme (IDE) (1:1000;
Abcam, #ab32216), anti-low-density lipoprotein
receptor-related protein (LRP1) (1:1000; Abcam,
#ab92544), anti-APP (C-terminal) (1:1000; Sigma-
Aldrich, #A8717), mouse anti-total Aβ (Aβ1–16) (1:1000;
Covance, #803001), and anti-apoE (1:1000; Abcam,
#ab20874) or GAPDH (1:1000; Bioworld; #AP0063).
Horseradish peroxidase-conjugated secondary antibodies
(Vector Laboratories) were used, and bands were visual-
ized using ECL plus detection system. GAPDH was uti-
lized as an internal control for protein loading and
transfer efficiency.
Enzyme activity assay
The enzyme activities of NEP and IDE were detected by
NEP and IDE activity assay kit, respectively (ANASPEC,
#72223 and #72231). Briefly, the frontal cortex of mice
was homogenized and the supernatants were collected
for the following experiment. Purified NEP or IDE en-
zyme was used as positive control, and the fluorescence
intensity was measured at Ex/Em = 490 nm/520 nm.
Quantitative analyses of images
All fluorescence micrographs were captured by a digital
microscope (DM4000B, Leica) with a constant exposure
time, offset, and gain for each immunofluorescent stain-
ing marker and analyzed by the Image-Pro Plus 6.0 Ana-
lysis System (Media Cybernetics Inc., San Francisco, CA,
USA). The frontal cerebral cortex in each section was
manually delineated. The area of positive signal of
GFAP, GS, Ibal, Aβ1–40, total-Aβ, thioflavine-S, or TR-
d3 was measured using the interest grayscale threshold
analysis with constant settings for minimum and max-
imum intensities for each staining marker [19]. The
number of total-Aβ or thioflavine-S-positive plaques in
the frontal cortex per section was quantified. The per-
centage area of positive signal was calculated by dividing
the area of positive signal to the total area in the region
of interest. The percentage area of TR-d3 in the dcLNs
was also detected with the same method. The fluores-
cence intensity of TR-d3 in the cortex was determined
along a corresponding linear region adjacent to the
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vessels as previously described [22]. For analysis of
phagocytosis and lysosomal degradation of microglia,
the percentage of area covered by double positive signal
for CD68, or Lamp1, and Iba1 was calculated [14]. For
analysis of total-Aβ (or apoE) accumulation within neu-
rons, astrocytes, and microglia, the percentage of area
covered by double-positive signal for total-Aβ (or apoE)
and NeuN, GFAP, or Iba1 was calculated, respectively.
The percentage of area covered by triple-positive signal
for Lamp1, Aβ, and Iba1 was also analyzed in the images
of the frontal cortex of AQP4−/−/APP/PS1 mice and
APP/PS1 mice. For analysis of AQP4 polarization, the
mean AQP4-immunoreactive intensity at the regions im-
mediately abutting vessels or pia maters and correspond-
ingly adjacent parenchymal domains was measured.
AQP4 polarization was obtained by comparing expres-
sion ratios of AQP4 at perivascular or pia surface versus
parenchymal domains [9, 19].
Statistical analysis
All data were expressed as means ± SEM using SPSS
software, version 16.0 (SPSS Inc., USA), and analyzed by
Student’s t test or ANOVA followed by Newman-Keuls
post hoc multiple comparison test as indicated in the
figure legends.
Results
AQP4 deletion exacerbated impairment of glymphatic
transport in 3-month-old APP/PS1 mice
Previous studies reported that glymphatic transport is
suppressed in both APP/PS1 mice [17] and AQP4−/−-
mice [9, 13, 15]. In our preliminary experiments, we
demonstrated that AQP4 deletion in APP/PS1 mice does
not induce spatial cognitive dysfunction at 3 months old
(Additional file 1: Supplemental Methods, Add-
itional file 2: Fig. S1a-f). Therefore, this age was chosen
to investigate the consequence of AQP4 deletion in
APP/PS1 mice on glymphatic function by examining
fluorescent tracer TR-d3 (3 kDa) penetration into and
clearance out of the brain (Fig. 1a, b). Thirty minutes
after injection into the cisterna magna, parenchymal dis-
tribution of TR-d3 was less in both AQP4−/− mice and
APP/PS1 mice than WT mice (p < 0.001; p < 0.05, re-
spectively). Notably, CSF tracer influx was further de-
creased in AQP4−/−/APP/PS1 mice compared to that of
AQP4−/− mice (p < 0.001) or APP/PS1 mice (p < 0.001)
(Fig. 1c, g). As shown by high magnification micrographs
of the frontal cortex (Fig. 1d), there was strong fluores-
cent intensity within the perivascular space and adjacent
brain parenchyma in WT mice. However, there were
only weak fluorescent signals in cortical parenchyma of
AQP4−/− mice and APP/PS1 mice. As for AQP4−/−/
APP/PS1 mice, the fluorescent tracer was only observed
at the outermost surface of brain parenchyma.
Quantification of the TR-d3 fluorescent intensity as a
function of the distance from the brain surface to the
parenchyma further demonstrated that AQP4 deletion
reduced glymphatic CSF influx in both WT mice and
APP/PS1 mice (both p < 0.001) (Fig. 1h). Consistently,
AQP4 deletion also suppressed macromolecule clearance
from the brain to the peripheral lymphatic system. One
hour after intrastriatal injection of TR-d3, AQP4−/−/
APP/PS1 mice displayed a high percentage of fluorescent
areas within the striatum (Fig. 1e, i), and a low percent-
age of fluorescent areas within the dcLNs, compared to
AQP4−/− mice (p < 0.01; p < 0.001, respectively) or APP/
PS1 mice (both p < 0.001) (Fig. 1f, j).
AQP4 deficiency increased accumulation of intraneuronal
Aβ accumulation without causing extracellular plaque
deposition in 3-month-old APP/PS1 mice
We evaluated whether AQP4 deletion exacerbates im-
pairments of glymphatic clearance, subsequently acceler-
ating Aβ-related neuropathology of 3-month-old APP/
PS1 mice. Neither thioflavine-S-positive plaques, nor
Aβ1–40 positive plaques, were visible in the cerebral cor-
tex of APP/PS1 mice and AQP4−/−/APP/PS1 mice
(Fig. 2a, b). However, AQP4 deficiency in APP/PS1 mice
intensified intraneuronal Aβ aggregation, as revealed by
double immunofluorescent staining of NeuN and total-
Aβ (Fig. 2c, f). Western blot results showed that the
expression levels of Aβ monomer and oligomers were
significantly increased in AQP4−/−/APP/PS1 mice (p <
0.05), but APP and its intracellular β-C-terminal frag-
ment (CTF-β) were not changed when compared with
those in APP/PS1 mice (Fig. 2d, g). AQP4 deficiency did
not affect expression of β-secretase, identified as BACE1,
and γ-secretase, a putative enzymatic complex contain-
ing PS1, in the cortex of WT mice and APP/PS1 mice.
Expression levels of LRP1, a functional protein for trans-
port of brain Aβ across the brain-blood-barrier, were
also comparable among the four genotype groups.
Transgenic APP/PS1 and/or AQP4 deletion did not
affect protein levels of NEP or IDE, two main enzymes
responsible for Aβ degradation. (Fig. 2e, h). However,
the enzyme activity of IDE, but not NEP, was upregu-
lated in AQP4−/−/APP/PS1 mice, when compared that in
APP/PS1 mice (p < 0.001) (Fig. 2i).
Eliminating reactive microgliosis increased Aβ
aggregation in the cerebral cortex of 3-month-old
AQP4−/−/APP/PS1 mice
Secreted IDE in the brain is mainly produced by micro-
glia [23]. Increased IDE activity might be involved in no
extracellular Aβ plaque formation in 3-month-old
AQP4−/−/APP/PS1 mice. To test this possibility, we ana-
lyzed the effect of AQP4 deletion on the activation of
microglia in the early pathological stage of APP/PS1
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Fig. 1 AQP4 deletion aggravates decreases of florescent tracer influx into, and efflux out of, the brain of 3-month-old APP/PS1 mice. a, b
Schematic images for intracisternal injection and intrastriatal injection of TR-d3. c Representative images of serial coronal brain sections from 1.0
mm anterior to 1.8 mm posterior to bregma (upper panel) and high magnification micrographs of the sections at the level of 0.5 mm anterior to
bregma (low panel) showing TR-d3 penetration into the brain parenchyma at 30min after intracisternal injection. d High magnification
micrographs of the cortex showing TR-d3 penetration into the perivascular space (star) and adjacent brain parenchyma (dotted line) at 30 min
after intracisternal injection. e Representative images of serial coronal brain sections from 1.0 mm anterior to 1.8 mm posterior to bregma (upper
panel) and high magnification micrographs of the sections at the level of 0.2 mm anterior to bregma (low panel) showing residue of TR-d3
within the striatum at 1 h after intracisternal injection. f Low (upper panel) and high (low panel) magnification micrographs of sections of the
dcLNs showing TR-d3 distribution at 1 h after intracisternal injection. g Quantification of intracisternally injected TR-d3 area fraction in the brain.
h Quantification of the mean fluorescence intensity of TR-d3 in the cerebral cortex after intracisternal injection. i Quantification of intrastriatally
injected TR-d3 area in the brain. j Quantification of intrastriatal injected TR-d3 in the dcLNs. Data were analyzed by the two-way ANOVA with
Tukey’s post hoc test or repeated two-way ANOVA with Tukey’s post hoc test. Data are mean ± SEM. n = 4 per group, *p < 0.05; **p < 0.01; ***p < 0.001
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mice. AQP4−/−/APP/PS1 mice showed more obvious ac-
tivation of microglia in the frontal cortex, as revealed by
a high percentage area of Iba1 immunostaining (p < 0.05,
versus APP/PS1 mice; Fig. 3a, b). However, both
AQP4−/−/APP/PS1 mice and APP/PS1 mice had mild ac-
tivation of astrocytes with a similar percentage area of
GFAP or GS immunopositive signals in their frontal cor-
tex (Fig. S2a-d). Consistent with astrocyte activation,
AQP4 expression was slightly but widely increased in
the brain parenchyma of APP/PS1 mice, impairing its
specific localization abutting microvessels and pia maters
(Fig. S3a, b).
Microglia and astrocytes participate in uptake and
phagocytosis of ISF Aβ [24, 25]. We investigated the ef-
fect of AQP4 deletion on these processes in APP/PS1
mice. AQP4−/−/APP/PS1 mice exhibited more Aβ aggre-
gation within the cytoplasm of Iba1-positive microglia
than APP/PS1 mice (p < 0.001; Fig. 3a, c). However, in
GFAP-positive astrocytes, Aβ immunoreactive products
were negligible in both AQP4−/−/APP/PS1 mice and
APP/PS1 mice (Fig. S2a, b). These results suggest that
microglia, rather than astrocytes, increase uptake of ISF
Aβ during the early pathological stages of AQP4−/−/
APP/PS1 mice.
Microglial phagocytosis of Aβ may offset impairment
of glymphatic clearance of Aβ caused by AQP4 deletion.
To test this possibility, microglia expressing CD68 and
Lamp1, markers of phagocytosis and lysosomal degrad-
ation [22] were examined. AQP4−/−/APP/PS1 mice
showed a higher percentage of area covered by CD68/
Fig. 2 AQP4 deletion increased intraneuronal Aβ and IDE activity without causing plaque formation in the cerebral cortex of 3-month-old APP/
PS1 mice. a, b Brain sections stained by thioflavine-S florescence and Aβ1–40 immunohistochemistry showing no Aβ plaque disposition. c Double
immunofluorescence for total-Aβ and NeuN. There was increased Aβ immunostaining in cerebral neurons of AQP4−/−APP/PS1 mice compared to
those in APP/PS1 controls. d, g Representative Western blot bands and densitometry analysis of APP, CTF-β, and Aβ monomer/oligomers. e, h
Representative Western blot bands and densitometry analysis of BACE1, PS1, LRP1, IDE, and NEP in the cortex. f Quantification of Aβ-positive area
fraction. i Enzyme activity assay of NEP and IDE. Data in f were analyzed by Student’s t test; other data were analyzed by the two-way ANOVA
with Tukey’s post hoc test. Data are mean ± SEM. n = 4 per group. *p < 0.05; **p < 0.01; ***p < 0.001
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Fig. 3 Increased microglial activation, and Aβ plaque deposition following eliminating microglia in AQP4−/−/APP/PS1 mice. a Double
immunofluorescence for total-Aβ and Iba1. Microglia were apparently activated in the cerebral cortex of AQP4−/−/APP/PS1 mice, compared to
those in APP/PS1 controls. Dot-like signals of total-Aβ (arrowheads) were frequently observed in AQP4−/−/APP/PS1 microglial cells. b, c
Quantification of Iba1-positive, and iba1 and total-Aβ double-positive area fraction in the cerebral cortex, respectively. d, f Double
immunofluorescence and quantification for CD68 and Iba1. CD68-positive microglia (arrowheads) were apparently increased in the cerebral
cortex of AQP4−/−/APP/PS1 mice, compared to those in APP/PS1 controls. e, g Double immunofluorescence and quantification for Lamp1 and
Iba1. Lamp1-positive microglia (arrowheads) were also apparently increased in the cerebral cortex of AQP4−/−/APP/PS1 mice. h, i Triple
immunofluorescence and quantification for Lamp1, total-Aβ, and Iba1. Aβ immunoreactive products were restrictively localized to Lamp1-positive
lysosome of Iba1-positive microglia. j Iba1 positive microglia were almost eliminated in both APP/PS1 mice and AQP4−/−/APP/PS1 with
clodronate liposome treatment. k, l Brain sections stained by thioflavine-S and Aβ1–40, respectively. Aβ plaque disposition was present at the
cerebral cortex of AQP4−/−/APP/PS1 mice received local injection of clodronate liposomes. m Double immunofluorescence for total-Aβ and
NeuN. Total-Aβ immunoreactivity (arrowheads) was increased within the cytoplasm of NeuN positive neurons of AQP4−/−/APP/PS1 mice injected
clodronate liposomes. n–s Quantification of Iba1, thioflavine-S, Aβ1–40, and total-Aβ-positive area fraction or number in the cerebral cortex,
respectively. Data in c, f, g, and i were analyzed by Student’s t test and in b, n, q, and s were analyzed by the two-way ANOVA with Newman-
Keuls post hoc test. Data are mean ± SEM, n = 4 per group, *p < 0.05; **p < 0.01; ***p < 0.001
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Iba1 or Lamp1/Iba1 double-positive signals in the frontal
cortex than APP/PS1 mice (p < 0.01, p < 0.05, respect-
ively; Fig. 3d–g). Moreover, Lamp1/Aβ/Iba1 triple im-
munostaining revealed that Aβ in the lysosome of
microglia was also increased in AQP4−/−/APP/PS1 mice
(p < 0.05; Fig. 3h, i), indicating increased phagocytic abil-
ity of Aβ by activated microglia.
To verify this speculation, clodronate liposomes, which
specifically depletes macrophages [20, 26, 27], were
injected into the frontal cortex to locally eliminate
microglia (Fig. 3j, n). Both thioflavine-S-positive plaques
and Aβ1–40-positive plaques were clearly observed in the
frontal cortex of AQP4−/−/APP/PS1 mice, but not APP/
PS1 mice, 5 days after treatment of clodronate liposomes
(Fig. 3k, l, o–r). AQP4−/−/APP/PS1 mice injected with
clodronate liposomes also noticeably improved accumu-
lation of intracellular Aβ (p < 0.001, versus PBS controls;
Fig. 3m, s). In addition, astrocytes in the frontal cortex
underwent elevated activation in both APP/PS1 mice
and AQP4−/−/APP/PS1 mice that received injection of
clodronate liposomes (Fig. S4a, b).
Increased apoE levels in the brain of 3-month-old
AQP4−/−/APP/PS1 mice
ApoE, a cholesterol transport protein, also regulates Aβ
metabolism, aggregation, and deposition [28]. A previous
study reported that the glymphatic system mediates
apoE transport within the brain [29]. Therefore, we in-
vestigated whether AQP4 deletion affects apoE levels in
the brain of 3-month-old APP/PS1 mice. Western blot
analysis showed that AQP4 deletion in either WT or
APP/PS1 mice resulted in high levels of apoE in the
cerebral cortex (p < 0.05, p < 0.001, respectively; Fig. 4a,
b). We further identified localization of apoE within dif-
ferent types of brain cells. Immunofluorescence revealed
that the immunoreactive products of apoE in WT mice
were localized within the cytoplasm of a small portion of
astrocytes (Fig. 4c) and neurons (Fig. 4d). AQP4 deletion
in APP/PS1 mice led to increased apoE in astrocytes as
well as neurons (Fig. 4c, d, f–h). This result is in agree-
ment with the view that apoE is generated mainly by
glial cells, whereas neurons predominantly produce apoE
under stressful conditions [30, 31]. Notably, there was a
high cellular co-localization of apoE and total-Aβ in
AQP4−/−/APP/PS1 mice, compared with APP/PS1 mice
(p < 0.001; Fig. 4e, i). This supports that there is a high
affinity between apoE and Aβ, which will facilitate the
formation of apoE/Aβ complexes [31–33].
Knockdown of apoE reduced intraneuronal aggregation
of Aβ in the brain of 3-month-old APP/PS1 mice with or
without AQP4 deletion
We further determined the effect of downregulating on
intraneuronal Aβ load by injection of AAV encoding
siRNAs targeting apoE into the frontal cortex (Fig. S5a-
d). The apoE levels dramatically decreased in 3-month-
old APP/PS1 mice and AQP4−/−/APP/PS1 mice that had
been pre-injected with the above AAV a month earlier,
as revealed by Western blot (Fig. 5a, b) and immuno-
staining (Fig. 5c, d). As expectedly, local knockdown of
apoE decreased intraneuronal accumulation of Aβ in
both APP/PS1 mice and AQP4−/−/APP/PS1 mice (both
p < 0.001; Fig. 5e–g). In addition, Western blot results
showed that administration of AAV encoding siRNAs
targeting apoE significantly decreased the level of Aβ
(p < 0.05; Fig. 5h, i), without altering APP and CTF-β
levels (Fig. 5h, i). These data indicate that dysfunction of
the glymphatic system mediated apoE clearance is a
main contributor to intraneuronal accumulation of Aβ
in the early pathological stages of AD.
Discussion
It is widely accepted that an age-related decline in Aβ
clearance is central to the onset of AD, although exact
pathogenesis of the disease remains elusive [1, 2]. APP/
PS1 mice serve as the most extensively used mouse
model of AD [34, 35]. This mouse line exhibits extracel-
lular Aβ deposition until 5–6 months old, mainly attrib-
uted to the decompensation of clearance ability under
long-term high levels of Aβ burden [36, 37]. Therefore,
we chose the 3-month-old time point to characterize the
profile of Aβ clearance related markers in the early stage
of this AD mouse model (Fig. 6). We further observed
the consequences of whole body knockout of the Aqp4
gene, local microglia elimination, and knockdown of the
apoE gene on Aβ load within neurons and extracellular
space of the frontal cortex, respectively.
Evidence from recent studies has highlighted that the
glymphatic system plays a dominant role in the clear-
ance of ISF Aβ [9–11], and its malfunction may be an
aggravating factor in brain aging and AD [11, 12, 38].
The present study has demonstrated that glymphatic
transport of a CSF tracer is suppressed in the 3-month-
old APP/PS1 brain prior to Aβ plaque deposit. This sup-
ports the view that glymphatic dysfunction potentially
serves as an early pathological marker of AD [17]. Glym-
phatic impairment could be associated with mislocaliza-
tion of AQP4 due to astrocyte activation [10–15]. In
addition, previous studies suggested that soluble Aβ pep-
tides, especially Aβ1–40, directly inhibit glymphatic trans-
port [17]. However, it remains to be determined which
mechanism plays the leading role in suppressing glym-
phatic function during the early stage of AD.
Evidence from several independent groups has re-
vealed AQP4-dependent glymphatic solute transport in
the rodent brain [9, 13, 15], despite others reporting
conflicting results [39, 40]. The present study further
confirms the importance of AQP4 in glymphatic
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clearance. Both CSF tracer influx and ISF tracer efflux
are decreased following the Aqp4 gene knockout with or
without transgenic APP/PS1. Notably, AQP4 deletion
dramatically reduces the transport rate of intrastriatal
TR-d3 into the dcLNs. This result further emphasizes
that AQP4-mediated rapid water transport is involved in
glymphatic macromolecule drainage from the brain into
the peripheral lymphatic system.
The current results have revealed that Aβ is aggre-
gated within frontal cortex neurons of APP/PS1 mice at
3 months old, compared to WT controls, but has yet to
cause obvious Aβ plaque formation. The absence of
Fig. 4 AQP4 deletion increased intraneuronal apoE aggregation in 3-month-old AQP4−/−/APP/PS1 mice. a, b Representative bands of Western
blot and densitometry analysis of apoE. c–e Double immunofluorescence of apoE/GS, apoE/NeuN, and apoE/total-Aβ, respectively. Note that
AQP4 deletion in APP/PS1 mice increased apoE immunoreactive intensity in GS-positive astrocytes and NeuN-positive neurons. ApoE and total-Aβ
double immunoreactive products were also accumulated. f–i Quantification of apoE, apoE/GS, apoE/NeuN, and apoE/total-Aβ-positive area
fraction in the cerebral cortex, respectively. Data in i were analyzed by Student’s t test; other data were analyzed by the two-way ANOVA with
Newman-Keuls post hoc test. Data are mean ± SEM, n = 4 per group, *p < 0.05; **p < 0.01; ***p < 0.001
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Fig. 5 AQP4 deletion increased intraneuronal apoE aggregation in 3-month-old AQP4−/−/APP/PS1 mice. a, b Representative bands of Western
blot and densitometry analysis of apoE and LRP1. c Immunofluorescence of apoE. ApoE expression was significantly decreased in the cerebral
cortex following local injection of AAV encoding apoE siRNAs. d Quantification of apoE-positive area fraction in the cerebral cortex. e Double
immunofluorescence of NeuN and total-Aβ. Total-Aβ expression was also obviously decreased in the cerebral cortex following local injection of
AAV encoding apoE siRNAs. f, g Quantification of total-Aβ and NeuN/total-Aβ-positive area fraction in the cerebral cortex, respectively. h, i
Representative bands of Western blot and densitometry analysis of APP, CTF-β, and Aβ monomers/oligomers in the cortex after local injection of
AAV encoding apoE siRNAs. Data were analyzed by two-way ANOVA with Newman-Keuls post hoc test. Data are mean ± SEM, n = 4 per group,
*p < 0.05; ***p < 0.001
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AQP4 does not cause Aβ plaque formation, but rather
exacerbates intraneuronal Aβ aggregation in the early
stage of this AD mouse model. This result supports the
view that build-up of Aβ within neurons may play a
crucial role in plaque formation [41–43].
The following compensatory mechanisms related Aβ
clearance might contribute to no Aβ plaque formation
despite an intensified glymphatic clearance dysfunction
caused by AQP4 deletion. First, there is normal expres-
sion level of LRP1, which is responsible for transfer of
Aβ outside the brain [6, 7]. Second, dural lymphatic
drainage remains intact. Recent studies have shown that
brain interstitial fluid and macromolecules can be trans-
ported into the dcLNs through meningeal lymphatics
[44–46]. Our previous studies have also suggested that
the extra cranial brain clearance pathway remains intact
in 6-month-old APP/PS1 mice, but the deposition of Aβ
plaques significantly increases after the mice received bi-
lateral ligation of afferent vessels of the dcLNs [47].
More importantly, clearance of Aβ may be improved by
activation of microglia [24, 25]. In the present study, Aβ-
positive products, and CD68, a phagocyte-associated
marker [22], are detected in cell bodies of activated
microglia in the frontal cortex of AQP4−/−/APP/PS1
mice. Furthermore, Lamp1/Aβ/Iba1 triple immunostain-
ing has revealed that a considerable portion of Aβ-
positive products are located within lysosomes of
AQP4−/−/APP/PS1 microglia. In addition, there was in-
creased activity of IDE, mainly produced by microglia
within the brain [23], in the cerebral cortex of AQP4−/−/
APP/PS1 mice. Together, these results indicate that
microglial phagocytosis and enzymatic degradation are
potentially beneficial to prevent accumulation of extra-
cellular Aβ. Indeed, clodronate liposomes that eliminates
microglia for only 5 days cause Aβ plaque deposition in
the frontal cortex of 3-month-old AQP4−/−/APP/PS1
mice.
Interestingly, eliminating microglia does not enhance
Aβ plaque formation in 3-month-old APP/PS1 mice,
which could be attributed to an alleviated impairment of
glymphatic transport compared to that in AQP4−/−/
APP/PS1 mice with the same age. In addition, we have
discovered a significant reduction of LRP1, and more se-
vere Aβ plaque deposition, in the brain parenchyma and
Fig. 6 Schematic diagram of our working model for the glymphatic system mediated Aβ and apoE clearance and microglia mediated Aβ
degradation synergistically preventing Aβ plague formation in the early stages of the AD mouse model. 3-month-old APP/PS1 mice show
extracellular and intraneuronal accumulation of Aβ because of the long-term of expression transgenic APP/PS1. Excessive interstitial Aβ may result
in activation of astrocytes with loss of perivascular AQP4 polarization, subsequently impairing glymphatic clearance of Aβ and apoE. On the other
hand, microglia undergo activation and promote Aβ clearance, potentially preventing Aβ plaque formation. AQP4 deletion exacerbates
glymphatic transport impairment and intraneuronal accumulation of Aβ and apoE, but Aβ plaques have not yet aggregated, which may be
related to the increase of phagocytosis of reactive microglia
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vascular amyloidosis of 12-month-old AQP4−/−/APP/
PS1 mice, compared with their APP/PS1 littermates
[19]. These results suggest that glial cell phagocytosis,
enzymatic degradation, glymphatic clearance, and LRP1-
mediated transport working together prevent Aβ plaque
formation. However, the compensatory roles of these Aβ
clearance systems are gradually diminished, resulting in
extracellular Aβ aggregation with pathological progres-
sion of AD.
Our experimental results have illustrated that the
absence of AQP4 does not increase reactive astroglo-
sis in cerebral cortex of 3-month-old APP/PS1 mice,
which is contrary to results found in microglia. Our
previous study demonstrated that 6-month AQP4−/−/
APP/PS1 mice have more extensive reactive gliosis
than APP/PS1 mice, and at 12 months a large number
of astrocytes around Aβ plaques undergo atrophy
[19]. An early study from our laboratory has reported
that AQP4 deficiency decreases Aβ uptake in cultured
astrocytes, and in turn attenuates changes in mitogen-
activated protein kinase pathways, finally reducing
astrocyte activity [48]. Similarly, reduced reactive
astroglosis is likewise observed in 7–9-month-old
AQP4−/−/5xTg-AD mouse brains [49]. These data to-
gether indicate that long-term loss of AQP4 not only
damages glymphatic clearance of Aβ, but also de-
creases astrocyte phagocytosis of Aβ, in turn exacer-
bating the pathological progression of AD.
ApoE, a lipid carrier protein, is produced by astro-
cytes and secreted as high-density lipoprotein-like
particles in the brain. ApoE can directly bind to Aβ
amino-acid residues [12–28], subsequently forming
apoE/Aβ complex within neurons and extracellular
space [31–33]. Co-deposition of apoE with Aβ is a
key step for Aβ fibrillization and plaque formation
[50, 51]. Therefore, blocking apoE/Aβ interaction may
be a promising strategy for improving clearance of
soluble Aβ from the brain, and preventing the onset
of AD. However, there is still lack of safe and effect-
ive routes to inhibit apoE aggregation within the
brain parenchyma. The current study has revealed Aβ
and apoE co-accumulation within neurons prior to
plague formation in 3-month-old APP/PS1 mice. A
recent study has reported that the glymphatic system
contributes to the delivery of CSF-derived apoE to
neurons. CSF apoE distribution in brain is reduced in
AQP4−/− mice [17]. Consistently, we have shown that
AQP4 deletion increases Aβ and apoE co-aggregation
within neurons, supporting that glymphatic dysfunc-
tion is an important factor in Aβ pathogenesis. More-
over, the current results suggest that knockdown of
apoE expression significantly attenuates intraneuronal
aggregation of Aβ. This is consistent with findings
reporting the mitigating effects of apoE knock-out on
fibrillar Aβ deposits and neurodegeneration in several
AD-Tg mouse models [52–55].
In addition, accumulated evidence has highlighted
that inheritance of the APOE ε4 allele is the stron-
gest known risk factor for sporadic AD [56, 57]. A
previous study has indicated that both apoE2, apoE3,
and apoE4 isoforms contribute to Aβ deposition in
APP/PS1 mice [58]. A recent study has revealed that
apoE secreted by glia stimulates neuronal Aβ pro-
duction with an ApoE4 > ApoE3 > ApoE2 potency
rank order [59]. Further study is necessary to iden-
tify which subtype apoE is affected by glymphatic
dysfunction in this AD model, due to the fact that a
facilitating effect of glymphatic transport of CSF-
derived apoE is in an isoform-specific manner
(apoE2 > apoE3 > apoE4) [17]. It is necessary to fur-
ther determine whether increased ApoE production
is also involved in accumulation of apoE in the brain
after deletion of AQP4. Exploring this issue is help-
ful to reveal the interaction between AQP4 and apoE
in the pathogenesis of AD.
Apart from Aβ, evidence from recent studies suggests
that apoE influencing tau pathology and tau-mediated
neurodegeneration is also in an isoform-dependent man-
ner [60, 61]. Furthermore, apoE ε4 accumulation impairs
glial responsiveness, lipid transport, and cerebrovascular
integrity and function, which might be independent of
Aβ-related pathways [31, 62, 63]. These results indicate
that promoting glymphatic clearance of macromolecular
metabolic proteins including Aβ, Tau, and apoE may
counteract pathological cascades of AD in multiple as-
pects, potentially delaying the onset and development of
the disease.
Conclusion
The present study has characterized pathological fea-
tures of Aβ clearance systems of 3-month-old APP/
PS1 mice. AQP4 deletion exacerbates glymphatic
clearance impairment with increases in intracellular
accumulation of Aβ and apoE in APP/PS1 brain. Fur-
thermore, it also improves IDE activity and microglia
phagocytosis without aggravating Aβ plaque depos-
ition and spatial cognitive dysfunction. Eliminating
microglial cells causes Aβ deposition in the brain of
AQP4−/−/APP/PS1 mice, but not APP/PS1 mice.
Knockdown of apoE reduce intraneuronal Aβ levels in
APP/PS1 mice with or without AQP4. These results
have preliminarily revealed an interactive compensa-
tion between glymphatic clearance and microglial
phagocytosis in inhibiting brain Aβ accumulation in
the early stage of AD-like progression. This might
provide a promising strategy for preventing the onset
of AD.
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Additional file 1. Morris water maze. The Morris water maze test was
conducted to measure mouse long-term spatial cognitive function, as de-
scribed previously [19]. Four Training was performed over 7 consecutive
days, with 4 trials per day. During the first two days, mice were trained to
find a dark-colored cylindrical platform with a diameter of 10 cm, sitting
0.5 cm above the water surface. Mice did not receive the next hidden
platform tests if they had apparent motor and/or visual deficits indicated
by low swimming speed (< 75 mm/s) or long escape latency (> 50 s). On
the 3rd day, the platform was submerged 1 cm below the surface of the
water and moved to the opposite quadrant. Escape latency, swimming
distance and swimming speed were calculated. On day 8, the hidden
platform was removed, allowing mice to swim freely in the pool for 60 s.
The percentage of time spent in the target quadrant and the number of
crossing where the platform had been previously located were analyzed.
Y-maze test. The Y-maze test was performed to evaluate mouse short-
term spatial working memory, as previously described [19]. One arm,
termed the novel arm, was blocked by a black baffle, allowing the mice
to only move in the other two arms for 5 min. Two hours later, the novel
arm was opened, allowing mice to freely move throughout the three
arms. The percentage of time traveled in, number of entries into the
novel arm, as well as traveling speed during the test, was calculated.
Mouse activity in the aforementioned behavioral apparatuses was col-
lected by a digital video camera connected to a computer-controlled sys-
tem (Beijing Sunny Instruments Co. Ltd., China). All tests were performed
by two independent experimenters, who were each blind to the treat-
ment schedule.
Additional file 2: Fig. S1. No obvious effects of AQP4 deletion on
spatial cognitive function of 3-month-old APP/PS1 mice. a, b The mean
escape latency and swimming speed during the training period of the
Morris water maze test. c The number of crossing the platform. d The
percentage of time in the target quadrant. e The number of entries into
the novel arm. f The percentage of time in the novel arm in the Y-maze.
Data in S1a, b were analyzed by repeated-measures ANOVA with post
hoc Student-Newman-Keuls test. Other Data were analyzed by ANOVA
with post hoc Student Newman-Keuls test. Data are means ± SEM. n = 12
per group. Fig. S2. AQP4 deletion did not affect astrocyte activation in
3-month-old APP/PS1 mice. a, b Double immunofluorescence and quanti-
fication for GFAP and total-Aβ in the cortex. c, d Immunofluorescence
and quantification for GS positive astrocytes in the cortex of APP/PS1
mice and AQP4−/−/APP/PS1 mice. Data are means ± SEM. n = 4 per
group, two-way ANOVA with Newman-Keuls post-hoc test. Fig. S3.
AQP4 polarization was impaired in the cerebral cortex of 3-month-old
APP/PS1 mice. a Double immunofluorescence for AQP4 and GFAP. b
Quantitative analyses of the AQP4 polarization. Data are means ± SEM.
n = 4 per group, Student’s t-test. **p < 0.01; ***p < 0.001. Fig. S4. In-
creased astrocyte activation in the cortex in 3-month-old APP/PS1 mice
and AQP4−/−/APP/PS1 mice receiving local injection of clodronate lipo-
somes. a, b Double immunofluorescence and quantification for total-Aβ
and GFAP in the cortex. Data are means ± SEM. n = 4 per group, two-
way ANOVA with Newman-Keuls post-hoc test. Fig. S5. An image shows
GFP expression in the cortex one month after injection of AAV encoding
apoE siRNAs. a GFP positive area represented where the AAVs was
injected. b-d Double immunofluorescence for GFP and GFAP. Note that
apoE siRNAs were expressed in GFAP positive astrocytes (arrowheads).
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